文献速递前列腺增生与排尿功能障碍

全基因组关联研究揭示孕激素受体在前列腺增生风险中的作用

Genome-wide association study identifies a role for the progesterone receptor in benign prostatic hyperplasia risk.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2020-11-20

该研究对良性前列腺增生(BPH)进行全基因组关联研究(GWAS),发现队列使用eMERGE网络中1942例病例和4730例对照,验证队列使用UK Biobank中5109例病例和161911例对照。发现队列识别出35个全基因组显著变异(P < 5 × 10-8),位于22个不同位点;验证队列确认了四个显著变异,分别位于15q11.2、22q13.2、2q24.2和11q22.1。其中rs1237696位于孕激素受体(PGR)基因内含子,P = 4.21 ×10-8,OR [95% CI] = 1.36 [1.22-1.52]。结论提示BPH GWAS鉴定的遗传变异可识别药物治疗靶点。

要点

  • BPH GWAS发现35个全基因组显著变异,验证4个位点。
  • rs1237696位于PGR基因内含子,与BPH风险相关(OR=1.36)。
  • PGR是已知BPH药物靶点,支持遗传学指导药物靶点发现。

核心结论

  • BPH GWAS鉴定的遗传变异可识别药物治疗靶点。

研究设计与样本

  • 发现队列:eMERGE网络1942例BPH病例和4730例对照。
  • 验证队列:UK Biobank中5109例病例和161911例对照。

主要发现

  • 发现队列识别35个全基因组显著变异(P < 5 × 10-8),位于22个不同位点。
  • 验证队列确认四个显著变异:rs8027714(15q11.2)、rs8136152(22q13.2)、rs10192133(2q24.2)、rs1237696(11q22.1)。
  • rs1237696位于PGR基因内含子,P = 4.21 ×10-8,OR [95% CI] = 1.36 [1.22-1.52]。

临床怎么用

  • PGR作为已知BPH药物靶点,其遗传变异关联支持进一步研究PGR激动剂等药物在BPH治疗中的应用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Benign prostatic hyperplasia (BPH) is common noncancerous prostate enlargement, which is usually associated with lower urinary tract symptoms (LUTS) and can lead to complex urinary, bladder, or kidney diseases. The majority of elderly men will be affected by BPH as age increases. METHODS: Here, we conducted a genome-wide association study (GWAS) of BPH using 1942 cases and 4730 controls from the Electronic Medical Records and Genomics network (eMERGE) as discovery cohort. We then used 5109 cases and 161,911 controls from UK Biobank as validation cohort. RESULTS: This GWAS discovered 35 genome-wide significant variants (P < 5 × 10-8), located at 22 different loci in discovery cohort. We validated four significant variants located at four different loci in validation cohort: rs8027714 at 15q11.2, rs8136152 at 22q13.2, rs10192133 at 2q24.2, and rs1237696 at 11q22.1. rs1237696 is an intronic variant on chromosome 11 in the progesterone receptor (PGR) gene (P = 4.21 ×10-8, OR [95% CI] = 1.36 [1.22-1.52]). PGR is a known drug target for BPH as the PGR agonist gestonorone caproate has been used to treat BPH in multiple countries. CONCLUSIONS: Our results suggest that genetic variants identified from BPH GWAS can identify pharmacologic targets for BPH treatment.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Li W, Klein RJ. Genome-wide association study identifies a role for the progesterone receptor in benign prostatic hyperplasia risk. Prostate Cancer Prostatic Dis. 2020. PMID: 33219367. doi:10.1038/s41391-020-00303-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。